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INTRODUCTION
Due to higher cardiovascular risk, resistant hyper-
tension is serious and requires special diagnosis and 
treatment of multidiscplinary team of hypertension 
specialist, nephrologist, intervential cardiologist or ra-
diologist and nurse. It is very important that patients 
understand the rationale for adherence to antihyper-
tensive therapy. Poor adherence is a major cause of 
lack of blood pressure control and it can be misleading 
in further diagnostics and treatment with detection of 
drugs in blood and/or urine. New devices like renal 
denervation were developed to interrupting the car-
diovascular disease continuum, the leading cause of 
death globally (1). Arterial hypertension is a perma-
nent increase of systolic blood pressure values above 
>140 mmHg and diastolic blood pressure values abo-
ve >90mmHg. It is a very important modifi able risk 
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factor connected with heart disease, cerebrovascular 
incident, chronic kidney failure and premature mor-
tality and disability and is one of the most important 
world health problems of today (2). Studies show that 
cardiovascular risk is doubled with every increase of 
blood pressure values by 20/10 mmHg and every re-
duction of systolic blood pressure value by 10 mmHg 
proportionally lowers the incidence of major cardio-
vascular disease events (stroke, heart failure, coronary 
disease) and reduces the all-cause mortality by 13% 
(3). Resistant hypertension (RH) is diagnosed when 
it is not possible to achieve recommended blood pre-
ssure values of <140/90 mmHg even aft er implemen-
ting the required lifestyle changes and incorporating 
at least three diff erent antihypertensive drugs in tre-
atment, including a diuretic (4). Cardiovascular mor-
bidity and mortality are a lot higher among RH po-
pulation when compared to the population suff ering 
from arterial hypertension (4). Renal denervation 
is one of the methods used for the treatment of RH. 
Many studies confi rm that RDN is eff ective in lowe-
ring BP in patients with RH with additional positive 
eff ects on blood glucose levels, OSA and multi-organ 
failure caused by hypertension (5-9).
Th e primary goal of the hypertension specialist is to 
determine which patients with resistant hypertension 
(RH) require renal denervation (RDN) procedure (1). 
New innovative devices therapies create an additional 
novel pathway of blood pressure lowering procedures 
and should be prescribed by a specialist hypertensi-
on clinic. In this study we investigate the characteri-
stics of early changes of blood pressure (BP) in RHpt 
undergoing RDN and the predictors of Ambulatory 
Blood Pressure Monitoring (ABPM) response and 
home blood pressure measurements (HBPM) early af-
ter RDN at University Hospital Merkur.
PATIENTS AND METHODS 
From a cohort of 80 resistant patients in Hypertension 
unit, only refractory RHpt (10.4%) were included in 
study, from which 12% have criteria for RDN. Resistant 
hypertension was confi rmed with 24h ABPM accor-
ding to European Society of Cardiology and European 
Society of Hypertension guidelines. In standardized 
stepwise screening protocol we selected patients with 
refractory RH (10). Approximately 30 % patients have 
severe OSA sy treating with CPAP, 35% were older>65 
years and 45% diabetics. Exclusion criteria were pa-
tients with kidney transplantation, pseudoresistance, 
inaccurate measurement techniques, nonadherence to 
treatment and a suboptimal medication regimen. Se-
condary causes of hypertension, hospitalisation due to 
a hypertensive emergency in this year, renal diameter 
<4mm and renal artery length < 20mm were exclusion 
criteria. Patients that presented with the anatomy of 
renal arteries incompatible with the procedure (mul-
tiple renal arteries), GFR <45/ml/min/1.73m2, diabe-
tes type 1 or type 2 with HbA1C >7.5% were excluded 
from the study. 
All participants with offi  ce BP >160 mmHg were pres-
cribed three or more diff erent antihypertensive drugs, 
including a diuretic, in maximally tolerated dosage. 
Th e following classes of medications were angioten-
sin-converting enzyme (ACE) inhibitors or angio-
tensin II receptor blockers (ARBs), calcium channel 
blockers (CCBs) and diuretics. Around 75% patients 
had combinations like ACEI+CCB+diuretic, 45% beta 
blockers, 40% sympatholytics, potassium sparing diu-
retic in 30 %.
All subjects measured 24 hours (h) BP monitoring 
(ABPM) to rule out white coat hypertension, and to 
confi rm the RH, before selecting patients for RDN. 
Patients were aged 60±6 years, 6.7±1 for number of 
antihypertensive drug classes included spironolactone 
use in doses from 50-100 mg, body mass index (BMI) 
was 36±3 kg/m2, estimated glomerular fi ltration rate 
(eGFR) was calculated using the Chronic Kidney Dis-
ease Epidemiology Collaboration (CKD-EPI) formula 
with eGFR 63±28 mlmin-1 1.73m2. 
Arterial stiff ness was determine in all 80 patients with 
RH and in part of patients aft er RDN using pulse pulse 
wave velocity (PWV, m/s), evaluated using the nonin-
vasive Agedio B900 device (Germany) (11). We used 
brachial pressure waveforms of superfcial arteries and 
this arm cuf based method makes use of a transfer 
function like method with the ARC Solver algorithm 
built in the Mobil-o-graph (11). An appropriate cuf-si-
ze we used to avoid poor blood pressure measurement 
aft er rest of 5 minutes. We measured PWV several ti-
mes in an ideal environment (patients were calmly in 
quietly room). 
Adherence was assessed through patient interview. We 
keep the regimens for the resistant hypertension ma-
nagement as simple as possible. We selecting optimal 
medication combinations at the most eff ective dosa-
ges based on the patient’s conditions to improve blood 
pressure control. 
Th is study was conducted in accordance with the 
amended Declaration of Helsinki. Th e study was 
approved by the hospital ethics committee and all par-
ticipants gave their informed written consent.
Statistical Analysis
Th e data were processed in the soft ware program SPSS. 
Statistical analysis of a data was performed using de-
scriptive statistics. Paired sample t-test were applied 
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for comparison of results. Th e level of statistical signif-
icance was set at p<0.05.
RESULTS 
A minority of RH patients (27, 35%) were male and 
were younger than their female counterparts (53.9 ye-
ars). Th e diference between sex was statistically signi-
fi cant for PWV (M/F= 8.1/9.2m/s, p>0.01). 
Primary endpoint of study was to evaluate effi  cacy 
and safety of early eff ect aft er RDN. Renal denerva-
tion signifi cantly reduced continuously blood pres-
sure measurement from maximum value 252/142 
mmHg (average 169/103 mmHg) to minimal value 
131/78 (average 144/91mmHg) 24 h aft er procedure 
(p<0.001). 
Signifi cant reduction in continuously blood pressure 
measurement 24h aft er renal denervation (-21/12 
mmHg) and home blood pressure measurements 
(-23/11 mmHg) 72 h aft er renal denervation was fo-
und in patients with normal (p<0.001) or moderate 
(p<0.05) elevated pulse wave velocity (for age 55-65y 
normal value is 6.5-7.7 m/s). 
Th e mean value of the total measured pulse wave ve-
locity value was higher than reference for age in older 
and diabetics and was 8.14 m/s. 
Th ere was no deterioration in kidney function aft er 
renal denervation with follow up of one year. Report-
ed rates of renal events were 0% for new renal artey 
stenosis. 
DISCUSSION 
Resistant hypertension patients oft en have comorbid 
cardiorenovascular conditions, such as heart failure, 
atrial fi brillation or chronic kidney disease (4). Th e dia-
gnosis of hypertension and treatment are based usu-
ally on daytime clinic blood pressure measurements. 
Evidence is that the asleep blood pressure better predi-
cts cardiovascular events than the awake or 24 h blood 
pressure mean (4). Th erapeutic restoration of normal 
physiologic blood pressure reduction during night-ti-
me sleep (circadial variation) is the most signifi cant 
independent predictor of decreased cardiorenovascu-
lar risk and the basis for the chronotherapy. Although 
chronotherapy is not uniformly recommended in the 
treatment of resistant hypertension, it is a cost-eff e-
ctive strategy for reducing cardiovascular risk and we 
have showed than circadian rhythm of blood pressure 
restoration and nephrotic proteinuria alleviation in a 
patient with chronic kidney disease aft er renal sym-
pathetic denervation in real life exist (9). We have pre-
viously proved for the frst time that RH patients have 
higher PWV (than according to age), and this resear-
ch confi rmed the diference between sex (11). In this 
study we have showed that PWV could be predictor 
aft er RDN procedure. What about real position and 
new date with RDN?
Th e results of early studies of renal denervation success 
were quite promising, but were lacking in sham-con-
trol which allows assessment of blood pressure redu-
ction due to eff ects unrelated to renal denervation. 
SYMPLICITY HTN-3 in 2014, the fi rst large prospe-
ctive, randomised, double-blinded and sham-contro-
lled study was did not meet its primary goal to prove 
signifi cant blood pressure reduction between the RDN 
group and sham-control. Th at caused a huge step back 
for RDN (12). However, many oversights have been 
found aft er detailed analysis and revision of the study: 
the fi rst one is the inexperience of the operators, 31% 
of all 111 operators had only performed one procedure 
before they were included in the study. Furthermore, 
the number of ablations diff ered from centre to centre. 
It is also estimated that approximately ¾ of patients did 
not receive ablations in all four quadrants of the renal 
arteries. In addition, a quarter of participants were of 
Afro-American heritage. Renal denervation has been 
found ineff ective among these patients due to their 
beta-1 adrenergic receptor polymorphism and lower 
renin plasma levels. Th e Afro-American population 
is frequently prescribed vasodilators for hypertension 
which have been connected with a lower response to 
RDN. Moreover, patients were randomised only two 
weeks aft er the adjustment of their antihypertensi-
ve medication. In that time the maximal eff ect of the 
administered drugs was not achieved and could have 
interfered with the results. During the study period, 
39% of patients had some changes in their prescribed 
antihypertensive medication (12).
Th e study recognised that the younger and older po-
pulation (<65 and >65) responded diff erently to the 
procedure (12). It is considered that isolated systolic 
hypertension (ISH), a dominant phenotype of hyper-
tension among elderly population, is connected to 
reduced response to RDN when compared to popu-
lation with combined systolic-diastolic hypertension 
(13). Th ese patients have increased vascular stiff ness, 
elevated pulse pressure and increased risk for stroke or 
myocardial infarction (13).
Another benefi t of the study is that the patients with 
OSA have been identifi ed as low responders to RDN 
(13). Because polysomnography was not performed 
before the randomisation, all data about OSA was
self-reported by participants (14).
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Despite many limitations, RDN is once again confi r-
med as safe method with minimal number of reported 
side eff ects (13,14). Despite the disappointing results, 
many saw the potential of RDN and kept up with furt-
her research in that fi eld (13-17).
Th e results of SPYRAL HTN-OFF MED, a multi-cen-
tric, randomised, sham-controlled study in 2017 with 
multi-electrode catheter (which contains four electro-
des and allows the administration of the radiofrequen-
cy energy in all four quadrants of the renal artery, and 
are able to reach accessory branches of the renal artery 
with the diameter <4 mm, which previous ablation 
systems were incapable of doing) fi nally proved that 
RDN indeed causes a statistically signifi cant reducti-
on of blood pressure in patients off  any antihyperten-
sive medication. Confounding factors, identifi ed in 
Symplicity HTN-3 study, have been eliminated in this 
study: patients were diagnosed with mild to modera-
te hypertension (SBP >150 mmHg and <180 mmHg, 
DBP >90 mmHg, mean 24-h ambulatory SBP >140 
mmHg and <170 mmHg), patients with ISH, that 
have been identifi ed as low-responders, were comple-
tely excluded and all procedures were done by highly 
experienced operators.
Th e key feature of the study is that the patients had to 
be off  any antihypertensive medication 3 to 4 weeks 
prior to and during the study period. Liquid chro-
matography and mass spectroscopy of urine and pla-
sma was done at baseline and 3 months in the study 
to ensure patients compliance with the absence of 
medication. Patients that presented with SBP >180 
mmHg that persisted for 72 h or more, were given 
antihypertensive treatment and were eliminated from 
the study. Patients were enrolled at 21 centres in USA, 
Japan, Australia and Europe (UK, Germany, Greece, 
Austria) (15). Th is diversity makes the results of the 
study applicable to the global population. Th e results 
confi rm a statistically signifi cant reduction of SBP -10 
mmHg (-15.0 do -4.9 mmHg, p<0.0004), DBP -5.3 
mmHg (-7.8 to -2.7 mmHg, p<0.0002) and 24h am-
bulatory BP -5.5/-4.8 mmHg in RDN arm of the study 
when compared to sham control. Lower risk of car-
diovascular mortality, coronary death and stroke were 
connected with the reduction of BP of this extent. 
Th at discovery has brought back faith in the effi  cacy of 
RDN in treating hypertension (15).
SPYRAL HTN-ON MED study is another interna-
tional, randomised, single-blind, sham-controlled 
study conducted to prove effi  cacy and safety of RDN 
in patients on standardised antihypertensive therapy 
consisting of up to three diff erent antihypertensive 
medications - thiazide diuretic, dihydropyridine cal-
cium-channel blockers, ACEI/ angiotensin receptor 
blockers or a β blocker with doses ≥50% of the maxi-
mum manufacturer’s recommended dosage. Exclusi-
on criteria include inappropriate renal artery anatomy, 
GFR<45mL/min, DM1 or poorly controlled DM2, one 
or more episodes of orthostatic hypotension, chronic 
oxygen support or mechanical ventilation other than 
nocturnal respiratory support for OSA, primary pul-
monary hypertension, pregnancy, nursing or planning 
to become pregnant, chronic NSAID treatment (ex-
cluding aspirin), the history of myocardial infarction, 
unstable angina pectoris, syncope or cerebrovascuar 
incidents within 3 months of screening, atheroscle-
rosis, with documented intravascular thrombosis or 
unstable plaques and night shift s. Drug adherence 
was assessed with liquid chromatography and mass 
spectroscopy of urine and plasma at baseline and 1, 
3 and 6 months post-procedure (16). Findings show 
a signifi cant reduction of mean 24-hour ambulatory 
SBP for -7 mmHg ( -12 to -2,1 mmHg, p=0,0059) and 
DBP for -4,3 mmHg (-7,8 to -0,8 mmHg, p=0,0174) 
compared to sham control. Adherence with prescribed 
medication was 60% . In a period of 6 months aft er 
the procedure was done no major adverse eff ects were 
registered.
Th e Swedish registry for RDN is endorsed by the Swe-
dish Society of Hypertension, Stroke and Vascular 
Medicine and it contains data about procedures and 
patient history as well as follow-up information for all 
RDN procedures done from 2011 to 2015: the RDN 
was successfully performed in 252 patients (97%). Six 
diff erent ablation systems were used for the procedure 
- Symplicity Flex, Symplicity Spyral, EnligHTN, Para-
dise, OneShot and Vessix. Only 7% patients presented 
with adverse eff ects (two renal artery dissections, one 
femoral artery dissection, one retroperitoneal bleeding, 
four localised hematomas and nine cases of minor 
adverse eff ects) (17). Th e reduction of offi  ce SBP ≥10 
mmHg was achieved in 58% of the participants, whi-
le 53% showed a decline in mean ambulatory BP ≥5 
mmHg, 33% responded in both offi  ce and ambulatory 
BP. Th ere were no registered changes in adjustment 
of medication as well as a decrease in GFR or signs of 
deterioration of renal function in predisposed patients 
(17). Renal denervation is proved eff ective in reduction 
of BP, but diff erent population groups respond diff eren-
tly to treatment. For the RDN procedure to achieve its 
maximal success, it is necessary to determine the truly 
eligible population and therefore correct inclusion cri-
teria. ISH, therapy of mineralocorticoid receptor ago-
nists or direct vasodilators, number of ablations per 
artery, the level of eGFR and obesity have already been 
determined as predictors of BP changes aft er RDN (14). 
Other factors that infl uence procedure success need to 
be identifi ed in the future, like PWV (18).
Th e effi  cacy and the consequences of redoing the pro-
cedure remain unknown. Th e correct inclusion criteria 
I. Prkačin, M. Stanković, D. Marković, M. M. Jakopović, A. Ivošević, J. Hrabar
Renal denervation: an early decrease in ambulatory and home blood pressure
Acta Med Croatica, 73 (2019) 303-308
307
for patients undergoing RDN needs to be determined 
in the future. Due to many important advancements 
and discoveries in the fi eld of RDN, it is only natural 
to assume that the procedure will become a part of a 
routine treatment of RH. Th e nonpharmacologic and 
pharmacologic management of resistant hypertension 
is largely based on consensus recommendations by 
experts. Algorithm-based approaches, such as renin 
profi ling to guide drug selection, require further va-
lidation. 
In terms of costs, there is no question pharmacoe-
conomically that eff ective blood pressure control in 
resistant hypertension with drugs and new innovati-
ve devices therapies is cheaper than treating the con-
sequences of hypertensive target organ damage. How-
ever, further trials are needed to confi rm these fi n-
dings in patients with hypertension and in those with 
resistant hypertension. Due to higher cardiovascular 
risk, resistant hypertension is serious and requires 
special diagnosis and treatment by a multidisciplinary 
team. It is of high importance that the evaluation of a 
patient with RH includes 24-hours monitoring of blo-
od pressure, home blood pressure (HBPM) and me-
asurement of PWV as a predictor of RDN response.
LIMITATIONS OF THE STUDY
Th e limitation of the analysis include the single centre 
study, lack of an untreated control group and lack of 
drug adherence testing. 
CONCLUSION
Renal denervation is an innovative procedure desi-
gned to achieve a reduction of BP (≥10 mmHg) in 
a short period of time. Th e purpose of RDN is not a 
complete cessation of antihypertensive medication. 
RDN lowering the cardiovascular risk and mortality. 
Home blood pressure monitoring improve adherence 
to medications by increasing patients involvement. 
In choosing patients for RDN is to determine arterial 
stiff ness using PWV measurements as a predictor of 
CV mortality, associating elevated PWV with poorer 
response to RDN procedures. We have now entered a 
new era of renal denervation, where the primary que-
stion has shift ed from “Does renal denervation actu-
ally lower blood pressure?” to “What is the appropria-
te application of renal denervation to reduce blood 
pressure and cardiovascular risk within the enormous 
hypertensive population.
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Probir bolesnika koji će imati najviše koristi od dodatne metode liječenja rezistentne hipertenzije denervacijom bubrež-
nih arterija, kojom se smanjuje tonus simpatičkog živčanog sustava selektivnom ablacijom živčanih ogranaka u stijenci 
bubrežnih arterija, iznimno je bitan. Cilj studije je bio utvrditi rani učinak denervacije bubrežnih arterija na sniženje krvnog 
tlaka unutar 24 sata (kontinuirano mjerenje) kao i na kućno mjerenje tlaka 72 sata poslije denervacije bubrežnih arterija. Od 
ukupnog broja bolesnika 10,4 % je imalo kriterije za rezistentnu hipertenziju a od njih svega 12 % za liječenje denervacijom 
bubrežnih arterija. Kod svih bolesnika s rezistentnom hipertenzijom učinjeno je mjerenje krutosti žila neinvazivnim mjera-
čem (Agedio B900, Njemačka). Za statističku analizu korišten je program SPSS, uz razinu značajnosti p < 0,05. Nakon de-
nervacije bubrežnih arterija dolazi do značajnog ranog sniženja tlaka mjereno kontinuiranim mjeračem tlaka: s prosječnog 
169/103 mm Hg prije na 144/91 mm Hg 24h nakon denervacije bubrežnih arterija (p <0,001). Značajno rano sniženje uočeno 
je u holteru tlaka (za -21/12 mm Hg) nakon 24 h i kućnom (-23/11 mm Hg) mjerenju nakon 72 sata od denervacije bubrežnih 
arterija, i to posebno u bolesnika s normalnim (p<0,001) ili blago povišenim (p<0,05) nalazom krutosti žila (referentna vrijed-
nost za dob 55-65 godina 6,5-7,7 m/s). Unutar 6 mjeseci prosječan broj antihipertenzivnih lijekova ostao je nepromijenjen 
(važno da se objektivizira učinak denervacije bubrežnih arterija). Nije zabilježeno neposrednih komplikacija denervacije 
bubrežnih arterija, bubrežna funkcija bila je stabilna. Povišena krutost žila mjerena neinvazivnim mjerenjem povezana je sa 
slabijim ranim sniženjem krvnog tlaka nakon postupka denervacije bubrežnih arterija. Prigodom odabira bolesnika za po-
stupak denervacije bubrežnih arterija mjerenjem krutosti žila dobiva se dodatna informacija koja može doprinijeti prigodom 
izbora bolesnika koji će imati najviše koristi od denervacije bubrežnih arterija.
Ključne riječi: renalna denervacija, rezistentna hipertenzija
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